Evidence map›Paper›PMID 31920016›Full record

ArticleJournal of Korean medical science2020

Clinical Role of the Chronic Obstructive Pulmonary Disease Assessment Test in Prediction of the Response to Treatment for Exacerbations.

Sunyoung Yoon, Tae Eun Kim, Tae Hyung Kim, Ju Ok Na, Kyeong Cheol Shin, Chin Kook Rhee, Sung Soo Jung, Kang Hyeon Choe, Kwang Ha Yoo

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal of Korean medical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01658020 (Clinical Trials to Evaluate Efficacy and Safety of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg After Multi-dose Oral Administration in Patients With Acute Bacterial Exacerbation of Chronic Obstructive Pulmonary Disease.), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01658020 phase3completednot on this map

Clinical Trials to Evaluate Efficacy and Safety of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg After Multi-dose Oral Administration in Patients With Acute Bacterial Exacerbation of Chronic Obstructive Pulmonary Disease.

TypeinterventionalSponsorDong Wha Pharmaceutical Co. Ltd.Ran2012 to 2014Enrolled345ConditionsChronic Obstructive Pulmonary DiseaseArmsZabofloxacin, Moxifloxacin
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Sunyoung YoonDepartment of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.ORCID https://orcid.org/0000-0002-4205-1434
Tae Eun KimDepartment of Clinical Pharmacology, Konkuk University School of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-7598-7602
Tae Hyung KimDivision of Pulmonology, Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.ORCID https://orcid.org/0000-0002-3863-7854
Ju Ok NaDivision of Allergy and Respiratory Disease, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea.ORCID https://orcid.org/0000-0002-9313-5216
Kyeong Cheol ShinRegional Center for Respiratory Disease, Department of Internal Medicine, Yeungnam University Medical Center, Yeungnam University College of Medicine, Daegu, Korea.ORCID https://orcid.org/0000-0003-1972-1847
Chin Kook RheeDepartment of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0003-4533-7937
Sung Soo JungDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.ORCID https://orcid.org/0000-0001-7990-3066
Kang Hyeon ChoeDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea.ORCID https://orcid.org/0000-0001-7197-6770
Kwang Ha YooDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea. khyou@kuh.ac.kr.ORCID https://orcid.org/0000-0001-9969-2657
Konkuk University · KRChungbuk National University · KRChungnam National University · KRChungnam National University Hospital · KRSoonchunhyang University · KRThe Catholic University of Korea Seoul St. Mary's Hospital · KRYeungnam University Medical Center · KR

Funding

Dongwha Pharm. Co., Ltd.
6 · The paper itself

Abstract

backgroundThe chronic obstructive pulmonary disease (COPD) assessment test (CAT) is a validated, eight-item questionnaire used to quantify the health status of patients. The aim of this study was to evaluate the usefulness of the CAT questionnaire as a tool to assess the response to treatment in acute exacerbations of COPD in an outpatient setting.

methodsA multicenter, phase 3 randomized controlled trial was conducted previously to examine the efficacy and safety of oral zabofloxacin for the treatment of COPD exacerbations. In the present post hoc analysis of the original study, patients with COPD exacerbation were categorized as responders or non-responders according to the respiratory symptoms persisting on day 10 (visit 3) of treatment. The CAT questionnaire was completed daily by patients at home from the initial visit to the second visit on day 5. Subsequently, the questionnaire was completed in the presence of a physician on days 10 (visit 3) and 36 (visit 4). Multivariate regression analysis was performed to determine the association between CAT scores and the therapeutic response.

resultsThe CAT scores decreased more rapidly in responders compared to non-responders during the first 5 days (23.3-20.4 vs. 23.5-22). Among responders, patients with higher severity of illness also revealed higher CAT scores on the first day of an exacerbation (mild, 19.8; moderate, 21.4; severe, 23.8; very severe, 28.6). Multivariate analysis revealed that a change in the CAT score during the first 3 days influenced the therapeutic response. A significant decrease in scores in the domains of sputum production, chest tightness, and activities of daily living was seen among responders.

conclusionEarly improvement in CAT scores may be associated with a more favorable response to the treatment of COPD exacerbations.

trial registrationClinicalTrials.gov Identifier: NCT01658020.

trial registrationClinical Research Information Service Identifier: KCT0000532.

Indexed as

Activities of Daily LivingAdministration, OralAgedAnti-Bacterial AgentsFemaleFluoroquinolonesHumansMaleMiddle AgedMultivariate AnalysisOdds RatioPredictive Value of TestsPulmonary Disease, Chronic ObstructiveRandomized Controlled Trials as TopicRespiratory Function TestsSeverity of Illness IndexAnti-Bacterial AgentsFluoroquinoloneszabofloxacinChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease Assessment TestExacerbationQuestionnaireTreatment Response

Identifiers

PMID31920016
PMCPMC6955431
OpenAlexW2998766271

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.